Latest Advances in Lung Cancer Research

The FDA rapidly approved Bristol Myers Squibb’s Opdivo for early-stage NSCLC, marking a major advancement in pre-surgical cancer treatment.

FDA skepticism challenges sintilimab’s approval for NSCLC, citing concerns over trial data exclusivity from China and its less favored endpoint of PFS.

The FDA has granted nivolumab (Opdivo) priority review as a neoadjuvant treatment for resectable NSCLC, based on promising CheckMate -816 trial results.

Lung cancer screening disparities persist for Black Americans, with USPSTF guidelines and risk models failing to adequately address racial differences in risk and diagnosis.

Moffitt Cancer Center seeks federal funding for a mobile unit to improve lung cancer screening rates, especially for marginalized communities, aiming for operational status by early 2024.

FDA grants breakthrough designation to FoundationOne Tracker, an assay for detecting MRD in cancer, aiding treatment decisions and relapse monitoring.

Medicare expands LDCT lung cancer screening eligibility, lowering age to 50 and pack-year history to 20, streamlining processes to improve early detection.

Lung cancer in never smokers presents unique molecular traits and lower mutation burdens, necessitating distinct treatment strategies and revised screening criteria.

A study developed and tested a remote intervention to improve the quality of life for lung cancer patients transitioning to post-treatment surveillance.

American Cancer Society report shows lung cancer deaths decline, boosting overall cancer survival despite persistent disparities and need for better screening.

FDA grants breakthrough designation to CLN-081, a targeted therapy for NSCLC with EGFR exon 20 mutations, showing promise in ongoing clinical trials.

Mount Sinai study shows earlier lung cancer diagnosis via CT screening significantly reduces deaths, underscoring the need for widespread screening adherence.